title: Neonatal blood pressure support: the use of inotropes, lusitropes, and other vasopressor agents.
abstract: A solid understanding of the mechanisms of action of cardiovascular medications used in clinical practice along with efforts to develop comprehensive hemodynamic monitoring systems to improve the ability to accurately identify the underlying pathophysiology of cardiovascular compromise are essential in the management of neonates with shock. This article reviews the mechanisms of action of the most frequently used cardiovascular medications in neonates. Because of paucity of data from controlled clinical trials, evidence-based recommendations for the clinical use of these medications could not be made. Careful titration of the given medication with close monitoring of the cardiovascular response might improve the effectiveness and decrease the risks associated with administration of these medications.
authors.affiliation: Center for Fetal and Neonatal Medicine and the USC Division of Neonatal Medicine, Children's Hospital Los Angeles and the LAC+USC Medical Center, Keck School of Medicine, University of Southern California, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA.
authors.forename: Shahab
authors.initials: S
authors.lastname: Noori
authors.forename: Istvan
authors.initials: I
authors.lastname: Seri
mesh_terms: D002316:Cardiotonic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000503:physiopathology; D004280:Dobutamine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004298:Dopamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004837:Epinephrine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006439:Hemodynamics; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D020105:Milrinone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011724:Pyridazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy* / Q000503:physiopathology; D000077464:Simendan; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014667:Vasopressins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D000077464:Simendan; D004280:Dobutamine; D020105:Milrinone; D004298:Dopamine; D004837:Epinephrine